Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial

Published:2019-12-26 Issue:4 Volume:22 Page:540-548
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Araki Eiichi¹^ORCID,Watada Hirotaka²^ORCID,Uchigata Yasuko³,Tomonaga Osamu⁴,Fujii Hitomi⁵,Ohashi Hiroshi⁶,Okabe Tadashi⁷,Asano Michiko⁸,Thoren Fredrik⁹,Kim Hyosung⁸,Yajima Toshitaka⁸,Langkilde Anna Maria⁹

Affiliation:

1. Department of Metabolic Medicine, Faculty of Life Sciences Kumamoto University Kumamoto Japan

2. Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan

3. Diabetes Center, Tokyo Women's Medical University School of Medicine Tokyo Japan

4. Diabetes and Lifestyle Center, Tomonaga Clinic Tokyo Japan

5. Internal Medicine, Tama‐center Mirai Clinic Tokyo Japan

6. Internal Medicine, Oyama East Clinic Tochigi Japan

7. Okabe Clinic Tokyo Japan

8. Research & Development, AstraZeneca K.K. Osaka Japan

9. Global Medicine Development, AstraZeneca Gothenburg Mölndal Sweden

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13922

Reference41 articles.

1. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association

2. Temporal patterns in overweight and obesity in Type 1 diabetes

3. Gender and Age – Dependent effect of type 1 diabetes on obesity and altered body composition in young adults

4. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

5. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated urinary albumin predicts increased time in range after initiation of SGLT2 inhibitors in individuals with type 1 diabetes on sensor-augmented pump therapy;Diabetology International;2024-08-06

2. A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02);Journal of Diabetes Investigation;2024-05-04

3. A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01);Diabetes Therapy;2024-01-13

4. SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations;Diabetes, Metabolic Syndrome and Obesity;2023-11

5. Gender representation in drug development studies for diabetes mellitus. A systematic review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3